Kirk Rebecca
Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK.
IDrugs. 2010 Feb;13(2):66-9.
The SMi's Eighth Annual Conference on Clinical Trials in CNS, held in London, included topics covering new therapeutic developments in the field of CNS disorders. This conference report highlights selected presentations on emerging clinical targets for the treatment of Alzheimer's disease, achievements of the Alzheimer's Disease Neuroimaging Initiative, computational assessment methods applicable to Alzheimer's disease and to the monitoring of suicidality, the accelerated antidepressive effect of PNB-01 (PharmaNeuroBoost NV; comprising a combination of pipamperone and citalopram), and clinical trials in amyotrophic lateral sclerosis and spinal muscular atrophy. Investigational drugs discussed also include begacestat (Pfizer Inc) and olesoxime (Trophos SA).
SMi举办的第八届中枢神经系统临床试验年度会议在伦敦召开，会议主题涵盖中枢神经系统疾病领域的新治疗进展。本会议报告重点介绍了关于阿尔茨海默病治疗新出现的临床靶点、阿尔茨海默病神经影像倡议的成果、适用于阿尔茨海默病及自杀倾向监测的计算评估方法、PNB - 01（PharmaNeuroBoost NV公司；由匹泮哌隆和西酞普兰组合而成）的加速抗抑郁作用，以及肌萎缩侧索硬化症和脊髓性肌萎缩症的临床试验。讨论的研究药物还包括贝加司他（辉瑞公司）和奥来司肟（Trophos SA公司）。
